{"id":392846,"title":"Example 1 - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-04-14","captureTimestamp":"2026-04-14T11:28:01.122000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/interval-prolongation/draft-guidance-industry-interval-prolongation-guidance-product-monograph-content-example-1.html","snippet":"Example 1 Example 1: Tabulation of the maximum mean increase in the QTc interval Treatment /Dose Multiple of Maximum Recommended Dose N Time of Maximum Mean Increase in QTc (Baseline- and Placebo-Adjusted) Maximum Mean Increase in the QTc (Baseline- and Placebo-Adjusted) #…","rawSnapshotUrl":"/api/snapshots/raw/392846","browseUrl":"https://replay.healtharchive.ca/job-6/20260414112801/https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/interval-prolongation/draft-guidance-industry-interval-prolongation-guidance-product-monograph-content-example-1.html#ha_snapshot=392846","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}